UK Markets close in 7 hrs 50 mins

Medtronic plc (0Y6X.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
107.36-0.75 (-0.69%)
As of 06:47PM GMT. Market open.
Sign in to post a message.
  • A
    Anonymous
    undervalued at these levels. I am buying down to $100. If 100 is breached I am taking out long calls. This company is solid. Beat up too badly.
  • L
    LA
    Needham lowered price target to $145 based on ER. MDT beat estimates but missed revenues based on analyst expectations. Miss was minimal and its a BUY BUY BUY here
  • a
    aabb
    MDT + ALPP Rising 800 % and AABB crypto stock Rising 4,000 % in 2021.
  • N
    Nao
    MDT had revenue headwinds due to hospitals differing many medical procedures during covid. As covid is lifing the pent up demand for needed med procedures should reflect in coming quarter(s) revenues. Im losding up.
  • B
    Bill mddb
    No doubt the Covid situation in Germany and other hot spots has dampened the outlook for elective procedures. The Delta variant here seemed to come & go, and was probably overblown in the press. Also no doubt that MDT's outlook will be key to how the market reacts to Q2 earnings.
  • P
    P
    ABT still taking new investors. MDT is dead money until the virus is gone. And who knows when that will be.
  • B
    Bill mddb
    I guess that the news today about J&J breaking up into drugs & medical devices in one company and consumer product in the other has been pressuring stocks like MDT , Stryker et. al. -- the drugs and medical devices company will have about $80 bil of revenue, more than double MDT. I also think $32 bil of revenue is enough for MDT to fund all the R&D it can invest effectively. So I don't see this as a big negative because MDT has been competing against JNJ all along. So when JNJ broken up into two stocks in 18-24 months I do not see how that is a much bigger threat then they are now. A part of the motivation to split into two has to be to contain all the baby powder & other consumer lawsuits.
  • b
    bill
    Jon Nagarian on CNBC said massive calls being bought (Jan 125s). Said to plan on heading to $130 in the next 2 months. Check it out.
  • L
    LA
    Bottom is in folks! Ride it back to $140
  • B
    Bill mddb
    It looks to be a tuff day for medical device stocks given that Stryker is indicated to open down 2% - 3% in reaction to their earnings report after the bell last night. I'm prepared to buy on a swoon. I already have a big % of my retirement account and portfolio account in MDT plc, as well as having about 25% cash at this point. If the market tanks and MDT dips enough I would add. I do expect to see a good earnings report and outlook. A wild card would be the impact, if any, and if material on MDT inventory conversion due to chip shortages. I remember well the Diabetes division woes when it suddenly, way before expected, an approved "G" device - could have been the 740G -- the first with an advanced technology to keep Type 1 in range based on MDT's feedback loop. They could manufacture the devices but could not source the sensors without building a manufacturing facility to produce them which delayed the new device & tech by 6-9 months. The Diabetes segment hasn't been able to catch up since then. Hopefully the new 780G unit parts will not be filling up storage space waiting for chips. MDT is in a different space than AAPL which just missed on Rev & EPS - $6 bil of revenue deferred due to chip shortages they said. Hopefully the G sensor capacity lesson prompted Omar to have key MDT supply chains subject to on-going analysis and review. Good Luck...
  • R
    Rob
    Great buying opportunity premarket
  • b
    bigboss
    (BEAT) $4..MC $31 m..Blockbuster product NEAR approval / NEW nasdaq stock =1000%+ UPSIDE !!

    "HeartBeam developed a mHealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ECG and examining the patient. It comprises a credit card size, 12 lead equivalent, ECG device, and a cloud-based diagnostic expert system. Studies designed by Harvard Medical School faculty have shown HeartBeam's performance to be equal or better than world-class cardiologists in diagnosing a heart attack. The technology features personalized diagnostic thresholds and novel heart attack ECG markers from which the application can also help Cardiologists locate a heart attack on a 3D model of the heart. HeartBeam's iCardiologist application utilizes Artificial Intelligence / Machine Learning to drive continuous improvements to the system's ability to provide patient analysis and improve the solution's predictive properties."

    #+#+
  • R
    Rex
    I can’t wait to get this for $114
  • j
    jsUVA
    Very positive news..
    Medtronic (NYSE:MDT) is in advanced talks to acquire Israeli startup Triple Jump for $300M, Calcalist reported on Sunday.
    The U.S medical device maker had already made an investment in Triple Jump in 2015 with an option to acquire it. Founded in 2015, Triple Jump is developing a small insulin pump patch with mobile connectivity.
    A deal is likely to further expand Medtronic’s (MDT) market presence in diabetes care
  • D
    DAVID
    why the big hit today?
  • R
    Roman
    Medtronic (NYSE:MDT) has lost ~4.7% in the post-market after a company announcement indicated a potential delay in its clinical program for Symplicity Renal Denervation System.
  • L
    LA
    Price Target CUT by Wellsfargo this morning....thats main reason why it's down.

    "Analysts at Wells Fargo cut their price target on the medical device maker to $144 a share from $151, while maintaining an overweight rating on the stock. Medtronic ( MDT ) has an average investment rating of outperform among analysts polled by Capital IQ, with a price target range of $129 to $155".
  • B
    Bill mddb
    I added on the dip. The fall seems to be from MDT not arguing against an independent safety board which obviously has standing to be able to recommend the full study be done instead of curtailing it because of the positive results so far into the study. If you are going to have a problem that's a good one to have, because there is nothing you can do about it unless it's unreasonable. So I added 100 shares to my pile. MDT said it would have no impact on FY22 EPS which is this year ending 4/30/22. MDT also said the study size should be reached before the end of this fiscal year ending 4/22. Sounds like a 6 month delay, but I could be off based on how you read the quote and news clip. If it was unreasonable MDT would probably argue against it. But you can't be aggressive because of enhanced risk if something does go wrong. They stated they already have real data for 3000 people which it appears makes this only a question of time and not efficacy
  • j
    jsUVA
    25% upside at current price w $149 target & 2% dividend!!!! Great opportunity!!!!
  • B
    Bill mddb
    Starting to interest me for averaging-in starting point. I'll wait for a while to see if anything else besides the C-19 flareups also surfaces. Like some black swan. How about a Bitcoin crash? On the other hand there are a lot of dollars on the sidelines to come in once the the current Covid spike and supply line bs calm down. So I'll wait & see what happens next week.